Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple blood test may predict immunotherapy success in lung cancer

NCT ID NCT07363811

Knowledge-focused Sponsor: Necmettin Erbakan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is looking at whether large granular lymphocytes (LGLs), a type of immune cell, can predict how well patients with advanced non-small cell lung cancer respond to the immunotherapy drug nivolumab. Researchers will measure LGL levels in 50 patients before and during treatment and compare them to tumor response and survival. The goal is to find a simple blood test that helps guide treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors predict which lung cancer patients will benefit most from nivolumab, leading to more personalized treatment.
What could go wrong
This is a small, early observational study (50 participants) that only looks for a link between LGLs and outcomes. It does not test a new treatment, so it may not change practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients diagnosed with metastatic non-small cell lung cancer who were followed up at the Medical Oncology Clinic of Necmettin Erbakan University Hospital and treated with nivolumab as second-line therapy.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histological and staging diagnosis of metastatic non-small cell lung cancer * ECOG performance score between 0 and 2 * No contraindications for nivolumab Exclusion Criteria: * Patients diagnosed with mNSCLC who received nivolumab as adjuvant or perioperative therapy * Those with a second primary malignancy undergoing active treatment * Those who have not signed the informed consent form * Those with additional hematological malignancies such as leukemia, lymphoma, or myelodysplastic syndrome * Those who have undergone palliative or curative radiotherapy within the last three months * Those with active viral/bacterial infections before nivolumab treatment * Patients who have used steroids in the last three months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic NSCLC - non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic NSCLC - non-small cell lung cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Necmettin Erbakan University Faculty of Medicine, Department of Medical Oncology

    RECRUITING

    Konya, Meram, 42090, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.